23 results on '"Munoz-Langa, J"'
Search Results
2. PREVALENCE OF CLINICAL MANIFESTATIONS AND ORTHOPEDIC ALTERATIONS IN PATIENTS WITH LIPEDEMA: A PROSPECTIVE COHORT STUDY
3. 2149P Catheter-related thrombosis in cancer patients: Data from the registry of thrombosis and neoplasia of SEOM (TESEO)
4. A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond six cycles in patients with glioblastoma (GEINO 14-01)
5. Retrospective study to identify clinical factors related to a high benefit of axitinib in mRCC: Results from AXILONG Spanish real-world study
6. Phase II trial of palbociclib in recurrent RB-positive anaplastic oligodendroglioma: A Spanish group for research in neurooncology (GEINO) trial
7. Preliminarily results of the Oncohabitats Study: A multicentre validation of overall survival (OS) estimation of patients with glioblastoma (GBM) using vascular biomarkers
8. Multi-parametric MR Imaging Biomarkers Associated to Clinical Outcomes in Gliomas: A Systematic Review
9. Impact of the combination of durvalumab (MEDI4736) plus olaparib (AZD2281) administered prior to surgery in the molecular profile of resectable urothelial bladder cancer: NEODURVARIB Trial
10. Randomized phase IIb clinical trial of continuation or non-continuation with six cycles of temozolomide after the first six cycles of standard first-line treatment in patients with glioblastoma: A Spanish research group in neuro-oncology (GEINO) trial
11. EXTENDING ADJUVANT TEMOZOLOMIDE LONGER THAN SIX CYCLES DOESN'T ADD ANY BENEFIT TO GLIOBLASTOMA PATIENTS ACCORDING TO THE RANDOMIZED GEINO-014 TRIAL
12. Extending temozolomide longer than six cycles in glioblastoma: Results of the randomized GEINO-014 trial
13. Lymphoscintigraphic findings in patients with lipedema
14. SPAZO2 (SOGUG): Validation of the international metastatic database consortium (IMDC) prognostic classification for targeted therapies as 2nd-line after 1st-line pazopanib (1stPz) in metastatic renal cell carcinoma (mRC)
15. Risk model for clinically relevant neutropenic event among patients with non hematological tumors receiving chemotherapy regimens not classified as high-risk for febrile neutropenia: results from a multicenter prospective cohort study (NEURISK)
16. 398PD - Extending temozolomide longer than six cycles in glioblastoma: Results of the randomized GEINO-014 trial
17. Quantitative assessment is essential for interpreting lymphoscintigraphy: Response to Ramin Sadeghi's letter to the editor
18. 895P - SPAZO2 (SOGUG): Validation of the international metastatic database consortium (IMDC) prognostic classification for targeted therapies as 2nd-line after 1st-line pazopanib (1stPz) in metastatic renal cell carcinoma (mRC)
19. 1452P - Risk model for clinically relevant neutropenic event among patients with non hematological tumors receiving chemotherapy regimens not classified as high-risk for febrile neutropenia: results from a multicenter prospective cohort study (NEURISK)
20. 9149 Phase II study of bevacizumab in combination with cisplatin and docetaxel as first line treatment of patients (p) with metastatic non squamous non-small-cell lung cancer (NSCLC)
21. PHASE II STUDY OF BEVACIZUMAB IN COMBINATION WITH CISPLATIN AND DOCETAXEL AS FIRST-LINE TREATMENT OF PATIENTS (P) WITH METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC): FINAL REPORT
22. Various Clinical Scenarios in Secondary Malignant Lymphedema.
23. Prevalence of clinical manifestations and orthopedic alterations in patients with lipedema: A prospective cohort study.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.